LONDON, April 22, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place on April 27, 2020.
Further details of the presentations are as follows:
Bay Street News